(Q37967108)

26 August 2017

title

Cutaneous lymphomas: molecular pathways leading to new drugs (English)

1 reference

26 August 2017

1

Reinhard Dummer

1 reference

26 August 2017

Simone M Goldinger

2

1 reference

26 August 2017

Antonio Cozzio

series ordinal

3

1 reference

26 August 2017

Lars E French

series ordinal

4

1 reference

26 August 2017

Maria B Karpova

series ordinal

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 December 2011

1 reference

Journal of Investigative Dermatology

26 August 2017

published in

1 reference

26 August 2017

volume

132

1 reference

26 August 2017

issue

3 Pt 1

1 reference

26 August 2017

page(s)

517-525

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2011.370

26 August 2017

exact match

0 references

cites work

Understanding rituximab function and resistance: implications for tailored therapy.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Small-molecule inhibitors of the human epidermal receptor family.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Proteasome inhibitor therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

MAP kinase signalling pathways in cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Demethylating agents in myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Non-Hodgkin lymphoma: an update

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

The interface between innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Evaluation of lymphangiogenic markers in Sézary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Classification of cutaneous lymphomas - an update

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Primary cutaneous B-cell lymphomas: then and now.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Cutaneous T-cell lymphoma cells are sensitive to rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Mechanisms of B-cell lymphoma pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Cell cycle kinases as therapeutic targets for cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Changes in oncomiR expression in CTCL cell lines during apoptosis induced by Notch inhibition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Histone deacetylase inhibitors: Potential in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Cell signaling and cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Increased angiogenesis in cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

The Toll receptor family and microbial recognition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Lymphangiogenesis and cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Clinical studies of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

How I treat mycosis fungoides and Sézary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Angiogenesis in cutaneous lymphoproliferative disorders: microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Cellular functions regulated by Src family kinases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

miRNA expression profiling of mycosis fungoides

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Cucurbitacin I inhibits Stat3 and induces apoptosis in Sézary cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Novel and highly recurrent chromosomal alterations in Sézary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

WHO-EORTC classification for cutaneous lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

HDAC family: What are the cancer relevant targets?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.370

7 January 2021

Identifiers

DOI

10.1038/JID.2011.370

1 reference

release_kku5oer4vjfanac7q6bva2zukq

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kku5oer4vjfanac7q6bva2zukq

24 November 2022

mapped directly with Wikidata item

1 reference